Tag Archives: jnj

HP Makes Long-Awaited Entry Into 3D Printer Market

The long-awaited entry of HP Inc. ( HPQ ) into the 3D printer market began Tuesday, with partners that include Nike ( NKE ), Autodesk ( ADSK ), ProtoLabs ( PRLB ) and BMW. The new printer line, called HP Jet Fusion 3D Printing Solution, “revolutionizes design, prototyping and manufacturing, and for the first time, delivers superior quality physical parts up to 10 times faster and at half the cost of current 3D print systems,” HP said in its press release . HP will compete with 3D Systems ( DDD ) and Stratasys ( SSYS ), the two largest providers of 3D printers, among others. HP is offering two 3D printers. They are the HP Jet Fusion 3D 3200 printer, designed for prototyping, and the Jet Fusion 3D 4200 printer, designed for prototyping and short-run manufacturing needs. Pricing on the 4200 model starts at $155,000 and will be delivered in late 2016. Pricing on the 3200 model starts at $130,000, with deliveries in 2017, HP said. Besides Autodesk, software partners include   Materialise ( MTLS ) and Siemens. Besides Nike, BMW and Proto Labs, co-development partners and strategic partners also include  Jabil  Circuit ( JBL ), Johnson & Johnson ( JNJ ) and Shapeways. HP stock fell in the stock market today , to 11.53. HP stock has been below its 50-day line most of this month. 3D Systems stock, though, rose nearly 1% Tuesday, and Stratasys stock rose nearly 2%.

Regeneron Arthritis Pain Drug Scores In Mid-Stage Trial

Regeneron Pharmaceuticals ( REGN ) said Monday that its experimental antibody for arthritis pain succeeded in a mid-stage trial, but shares were flat in early trading as the results were expected. The study enrolled 421 sufferers of moderate-to-severe hip and knee pain who’d been unsuccessful with standard painkillers. After 16 weeks of treatment, the group taking Regeneron’s fasinumab had improved by more than 3 points on a 10-point pain scale, significantly better than the placebo group. About 17% of the group taking fasinumab experienced adverse events, Regeneron said, including non-inflammatory joint pain, prickling and burning sensations in the skin, numbness and swelling. The investigators also did extensive imaging of the subjects, because the class of medicines to which fasinumab belongs — nerve growth factor (NGF) antibodies — has been associated with joint damage. They wound up excluding 2% of subjects due to imaging results, and five patients among the remainder suffered subchondral insufficiency fractures, or stress fractures on abnormal bones. Regeneron stock was near 377 in early trading on the stock market today . Shares touched an 18-month below 349 in late March, and Regeneron stock has a weak IBD Composite Rating of 47, putting it among the lower half of all stocks on the basis of key metrics such as earnings and sales growth. Regeneron had already signaled that the trial was going well earlier this year by starting a large phase-three trial of the drug, so the results weren’t especially surprising to analysts. It also lost a potential competitor in late March, when Johnson & Johnson ( JNJ ) stopped development of its own NGF antibody fulranumab, which was in late-stage trials for arthritis pain. RBC Capital Markets analyst Adnan Butt wrote at the time that J&J’s decision was based on pipeline prioritization, not on any problems with the drug itself. On Monday, Butt praised the effectiveness of fasinumab in the trial but wrote that the safety “bears watching.” “Overall, should this program succeed, it could be another blockbuster candidate, which unlike others could be an upside driver since it comes with regulatory and mechanistic safety concerns, hence is not a major focus for investors at this time, aside from a development cost and timeline standpoint,” Butt wrote in his research note.

Abbott Boosts Cardio Device Business With $25 Billion St. Jude Buy

Two giants in cardiac devices agreed to merge Thursday, as Abbott Laboratories ( ABT ) announced an agreement to acquire  St. Jude Medical ( STJ ) in a deal worth $25 billion. Abbott agreed to pay $46.75 plus 0.8708 Abbott share for every St. Jude share. Based on Abbott’s five-day average share price, the deal valued St. Jude shares at $85 apiece. St. Jude stock was up more than 25% in morning trading on the stock market today , near 78, while Abbott stock was down more than 7%, below 41. Abbott said that the deal will add 21 cents to its EPS next year and 28 cents the following year. It expects to save $500 million in costs from the combination by 2020. Abbott will also assume or refinance St. Jude’s $5.7 billion in debt. The move will greatly enlarge Abbott’s cardiovascular device business, which now represents 19% of its revenue. “St. Jude Medical’s strong positions in heart failure devices, atrial fibrillation and cardiac rhythm management complement Abbott’s leading positions in coronary intervention and transcatheter mitral repair,” said Abbott’s press release. “Together, the company will compete in nearly every area of the cardiovascular market and hold the No. 1 or 2 positions across large and high-growth cardiovascular device markets.” Leerink analyst Danielle Antalffy agreed. St. Jude’s flat-to-negative sales growth over the last few years picked up to 8% in Q1, and she wrote in a research note that it’s set up to continue, while Abbott looked to be growing only in the low single digits. Antalffy also wrote that a competing bid is unlikely. “The most logical buyer beyond Abbott in our view would be Johnson & Johnson ( JNJ ),” Antalffy wrote. “In our meetings with J&J in mid-2015, management emphasized that the company is not interested in what they deemed ‘value’ markets within MedTech, specifically calling out cardiac rhythm management (nearly 30% of St. Jude’s total sales) and drug-eluting stents.” The deal announcement came on a busy day for M&A in medical field. Biotech Medivation ( MDVN ) confirmed that it had received an unsolicited $9.3 billion bid from big pharma Sanofi ( SNY ), while AbbVie ( ABBV ), which used to be Abbott’s biopharma division before it was spun out, agreed to buy another cancer-focused biotech, Stemcentrx, for $5.8 billion.